Geoffrey Liu
University Health Network · 1,385 works · 41,665 citations · h-index 95
Top works
- Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
- Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer
- Patient preferences for oral versus intravenous palliative chemotherapy.
- A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25
- Probability of Cancer in Pulmonary Nodules Detected on First Screening CT
- Role of KRAS and EGFR As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21
- Molecular profiling of non-small cell lung cancer and correlation with disease-free survival.
- First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer
- Sensitive tumour detection and classification using plasma cell-free DNA methylomes
- Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
- Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial
- Prognostic and Predictive Gene Signature for Adjuvant Chemotherapy in Resected Non–Small-Cell Lung Cancer
- Obesity, metabolic factors and risk of different histological types of lung cancer: A Mendelian randomization study
- Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations.
- Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.
- Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes
- Prognostic and Predictive Importance of p53 and RAS for Adjuvant Chemotherapy in Non–Small-Cell Lung Cancer
- Transport of amphipathic anions by human multidrug resistance protein 3.
- Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer
- XPD and XRCC1 Genetic Polymorphisms Are Prognostic Factors in Advanced Non—Small-Cell Lung Cancer Patients Treated With Platinum Chemotherapy